• Company
• ‘Prevent MI recurrence through efficient LDL-C control'
• by Whang, byung-woo Nov 5, 2024 05:45am

• Company
• New oHCM drug 'Camzyos' nearing approval for reimb in KOR
• by Eo, Yun-Ho Nov 5, 2024 05:45am

• Policy
• Reimb standards that prevent abuse of HA Eye Drops imminent
• by Lee, Tak-Sun Nov 5, 2024 05:45am

• Company
• 'Nabota' generated KRW 115.8B over 9 mths in foreign mkt
• by Chon, Seung-Hyun Nov 5, 2024 05:45am

• Company
• 'SGLT2·DPP4' comb market records robust growth
• by Kim, Jin-Gu Nov 4, 2024 05:48am

• Company
• Will the polycythemia vera drug Besremi be reimb in KOR?
• by Eo, Yun-Ho Nov 4, 2024 05:48am

• Company
• K-Bios globally present immuno-oncology drugs
• by Son, Hyung Min Nov 4, 2024 05:48am

• Company
• Reimb of Vocabria+Rekambys for HIV gains attention
• by Eo, Yun-Ho Nov 4, 2024 05:48am

• Policy
• Anticipating reimb for DPP4·SGLT2 combination drugs
• by Lee, Jeong-Hwan Nov 1, 2024 05:51am

• Opinion
• [Reporter's View] Address Actions to drug substitution
• by Lee, Jeong-Hwan Nov 1, 2024 05:51am